Related Experiment Video

Updated: Dec 10, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.6K

Exploiting defects in homologous recombination repair for metastatic, castration-resistant prostate cancer

Vincent Chau1, Ravi A Madan1, William D Figg1

  • 1Genitourinary Malignancies Branch, National Institutes of Health , Bethesda, MD, USA.

Cancer Biology & Therapy
|August 27, 2020
PubMed

Insights

Testing for homologous recombination gene alterations in metastatic prostate cancer patients is beneficial. Olaparib demonstrated improved outcomes in patients with BRCA1, BRCA2, or ATM alterations.

Area of Science:

  • Oncology
  • Genetics
  • Genomic Medicine

Background:

  • Metastatic castration-resistant prostate cancer (mCRPC) presents significant treatment challenges.
  • Identifying specific genetic alterations can guide targeted therapy selection.
  • Homologous recombination (HR) pathway genes are implicated in prostate cancer development and progression.

Purpose of the Study:

  • To evaluate the efficacy of olaparib in patients with mCRPC harboring HR gene alterations.
  • To establish the rationale for routine genetic testing in mCRPC.

Main Methods:

  • The PROfound trial, a randomized controlled study.
  • Inclusion of patients with mCRPC and specific HR gene alterations (e.g., BRCA1, BRCA2, ATM).
  • Comparison of olaparib versus standard of care therapies.

Main Results:

  • Olaparib significantly improved progression-free survival (PFS) in patients with BRCA1, BRCA2, or ATM alterations.
  • Objective response rate (ORR) and time to pain progression were also improved with olaparib.
  • Demonstrated efficacy of olaparib in a genomically-selected mCRPC population.

Conclusions:

  • Genetic testing for HR alterations is recommended for all patients with mCRPC.
  • Olaparib is an effective treatment option for mCRPC patients with specific HR gene alterations.
  • Further research may clarify overall survival benefits and explore other HR pathway alterations.
Keywords:
DNA repairHomologous recombinationmetastatic prostate cancerolaparib

More Related Videos

Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model06:32

Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model

Published on: November 4, 2022

6.2K
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.1K

Related Concept Videos

Mismatch Repair01:20

Mismatch Repair

Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
6.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K